Capsaicin |
Catalog No.GC14065
One-Click Copy Product Info
|
Capsaicin is a highly selective agonist for the transient receptor potential cation channel, subfamily V, member 1 (TRPV1), a ligand-gated, nonselective cation channel, preferentially expressed on small-diameter sensory neurons.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 404-86-4
Sample solution is provided at 25 µL, 10mM.
Capsaicin is a highly selective agonist for the transient receptor potential cation channel, subfamily V, member 1 (TRPV1), a ligand-gated, nonselective cation channel, preferentially expressed on small-diameter sensory neurons [1]. capsaicin inhibits CYP1A2, CYP2C9, and CYP2C19, with IC50 values of 2.1, 2.0, and 3.2 μM, respectively, and inhibits CYP2B6, CYP2D6, CYP3A4, and CYP3A5 with extrapolated IC50 values of 24, 18, 38, and 12 μM, respectively [2].
Capsaicin inhibited Human cervical carcinoma HeLa growth (IC50 ～30 μM) and increased intracellular calcium, with effect blocked by capsazepine [3]. Capsaicin induced Human glioblastoma A172 apoptosis at ≥200 μM, not inhibited by capsazepine or BAPTA/AM 250 μM reduced basal generation of ROS and lipid peroxidation H2O2 reduced apoptosis, while NAC enhanced [4]. Capsaicin reduced Human urothelial cancer RT4 growth (IC50=80 μM) via a TRPV1-dependent process, induced cell cycle arrest in G0/G1 phase Apoptosis occurred [5].
Capsaicin pretreated ICR mice CD-1 mice with 2.5 μmol reduced VC-induced (5.8 mol) and TPA-promoted tumor incidence (by 62%) at 22 weeks (ICR) 1 μmol topical capsaicin 24 and 1 hr before, also significantly inhibited tumors induced by topical BP (0.3 μmol) then promoted with TPA (CD-1) [6]. Gavage with capsaicin significantly elevated phase II enzymes in liver and colon Oral capsaicin at 500 ppm for 4 weeks significantly inhibited ACF formation induced by AOM (20 mg/kg body weight, once a week for 2 weeks) In a 38-week study, 500 ppm capsaicin during the 4-week initiation phase significantly reduced (60%) incidence of colonic adenocarcinoma [7].
References:
[1]. Bley, K.; Boorman, G.; Mohammad, B.; McKenzie, D.; Babbar, S. A comprehensive review of the carcinogenic and anticarcinogenic potential of capsaicin. Toxicol. Pathol. 2012, 40, 847-873.
[2]. Babbar S., Chanda S., Bley K. (2010). Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin. Xenobiotica 40, 807-16.
[3]. Takahata K., Chen X., Monobe K., Tada M. (1999). Growth inhibition of capsaicin on HeLa cells is not mediated by intracellular calcium mobilization. Life Sci 64, PL165-71.
[4]. Lee Y. S., Nam D. H., Kim J. A. (2000). Induction of apoptosis by capsaicin in A172 human glioblastoma cells. Cancer Lett 161, 121-30.
[5]. Amantini C., Ballarini P., Caprodossi S., Nabissi M., Morelli M. B., Lucciarini R., Cardarelli M. A., Mammana G., Santoni G. (2009). Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in an ATM-dependent manner. Carcinogenesis 30, 1320-29.
[6]. Surh Y. J., Lee R. C., Park K. K., Mayne S. T., Liem A., Miller J. A. (1995). Chemoprotective effects of capsaicin and diallyl sulfide against mutagenesis or tumorigenesis by vinyl carbamate and N-nitrosodimethylamine. Carcinogenesis 16, 2467-71.
[7]. Yoshitani S. I., Tanaka T., Kohno H., Takashima S. (2001). Chemoprevention of azoxymethane-induced rat colon carcinogenesis by dietary capsaicin and rotenone. Int J Oncol 19, 929-39.
| Cell experiment [1]: | |
|
Cell lines |
Human colorectal carcinoma cells (SW480, LoVo and HCT-116) |
|
Preparation Method |
The cells were grown at a concentration of 2×105 cells/ml and then treated with capsaicin at concentrations or time points indicated in figure legends. |
|
Reaction Conditions |
0, 50 and 100 µM for 0, 1, 2, or 3 days |
|
Applications |
Growth of all three human colorectal cancer cell lines was inhibited by capsaicin treatment in a dose- and time-dependent manner. Although 50-µM capsaicin treatment decreased cell growth to some extent, significantly retarded cell growth was observed in cells treated with 100 µM of capsaicin. |
| Animal experiment [2]: | |
|
Animal models |
Male Swiss albino mice |
|
Preparation Method |
Group 1 (control) received olive oil throughout the course of the experiment. Group 2 were treated with BP (50 mgkg-1 dissolved in olive oil) orally twice a week (Day 1 and Day 4) for four successive weeks. Group 3 received capsaicin (10 mgkg-1 dissolved in olive oil) intraperitoneally once a week for 14 weeks to assess the cytotoxicity, if any, induced by capsaicin. Group 4 (BP + capsaicin) received BP (as for Group 2) along with capsaicin (10 mg kg-1 dissolved in olive oil) intraperitoneally. Capsaicin treatment was started 1 week before the first dose of BP and continued for 14 weeks |
|
Dosage form |
Intraperitoneal injection, 10 mgkg-1 week-1 for 14 week |
|
Applications |
Capsaicin pretreatment resulted in a free radical quenching effect, thereby significantly preventing the peroxidation of lipids in Group 4 animals. |
|
References: [1]: Lee S. H., Richardson R. L., Dashwood R. H., Baek S. J. (2011). Capsaicin represses transcriptional activity of β-catenin in human colorectal cancer cells. J Nutr Biochem. |
|
| Cas No. | 404-86-4 | SDF | |
| Chemical Name | (E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide | ||
| Canonical SMILES | CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC | ||
| Formula | C18H27NO3 | M.Wt | 305.41 |
| Solubility | ≥ 15.27 mg/mL in DMSO, ≥ 52.3 mg/mL in EtOH with gentle warming | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2743 mL | 16.3714 mL | 32.7429 mL |
| 5 mM | 654.9 μL | 3.2743 mL | 6.5486 mL |
| 10 mM | 327.4 μL | 1.6371 mL | 3.2743 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)